{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:10:10Z","timestamp":1762956610948,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003176","name":"Ministerio de Educacion Cultura y Deporte","doi-asserted-by":"crossref","award":["FPU15\/03434"],"award-info":[{"award-number":["FPU15\/03434"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0012\/0012","PI14\/00442","PI17\/01606"],"award-info":[{"award-number":["RD16\/0012\/0012","PI14\/00442","PI17\/01606"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The initial management of rheumatoid arthritis (RA) has a high impact on disease prognosis. Therefore, we need to select the most appropriate treatment as soon as possible. This goal requires biomarkers of disease severity and prognosis. One such biomarker may be the presence of anti-carbamylated protein antibodies (ACarPA) because it is associated with adverse long term outcomes as radiographic damage and mortality. Here, we have assessed the ACarPA as short-term prognostic biomarkers. The study was conducted in 978 prospective early arthritis (EA) patients that were followed for two years. Our results show the association of ACarPA with increased levels of all the disease activity measures in the first visit after arthritis onset. However, the associations were more significant with the high levels in local measures of inflammation and physician assessment than with the increases in systemic inflammation and patient-reported outcomes. More notably, disease activity was persistently increased in the ACarPA positive patients during the two years of follow-up. These differences were significant even after accounting for the presence of other RA autoantibodies. Therefore, the ACarPA could be considered short-term prognostic biomarkers of increased disease activity in the EA patients.<\/jats:p>","DOI":"10.1038\/s41598-021-89502-y","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T10:09:20Z","timestamp":1620727760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies"],"prefix":"10.1038","volume":"11","author":[{"given":"Cristina","family":"Regueiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Nu\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Triguero-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Villalba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"B\u00f3veda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Mart\u00ednez-Feito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Conde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidoro","family":"Gonz\u00e1lez-Alvaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"89502_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha, D. & Smolen, J. S. Diagnosis and management of rheumatoid arthritis: A review. JAMA 320, 1360\u20131372 (2018).","journal-title":"JAMA"},{"key":"89502_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/annrheumdis-2014-206047","volume":"74","author":"JAB van Nies","year":"2015","unstructured":"van Nies, J. A. B., Tsonaka, R., Gaujoux-Viala, C., Fautrel, B. & van der Helm-van Mil, A. H. M. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann. Rheum. Dis. 74, 806\u2013812 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685\u2013699 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/keq230","volume":"50","author":"DPC de Rooy","year":"2010","unstructured":"de Rooy, D. P. C., van der Linden, M. P. M., Knevel, R., Huizinga, T. W. J. & van der Helm-van Mil, A. H. M. Predicting arthritis outcomes\u2014What can be learned from the Leiden Early Arthritis Clinic?. Rheumatology (Oxford) 50, 93\u2013100 (2010).","journal-title":"Rheumatology (Oxford)"},{"key":"89502_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","volume":"76","author":"B Combe","year":"2017","unstructured":"Combe, B. et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann. Rheum. Dis. 76, 948\u2013959 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo, M. L. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheumatol. 38, 44\u201348 (1995).","journal-title":"Arthritis Rheumatol."},{"key":"89502_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/rheumatology\/kei228","volume":"45","author":"OMR Westwood","year":"2006","unstructured":"Westwood, O. M. R., Nelson, P. N. & Hay, F. C. Rheumatoid factors: What\u2019s new?. Rheumatology (Oxford) 45, 379\u2013385 (2006).","journal-title":"Rheumatology (Oxford)"},{"key":"89502_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrrheum.2011.76","volume":"7","author":"WJ van Venrooij","year":"2011","unstructured":"van Venrooij, W. J., van Beers, J. J. B. C. & Pruijn, G. J. M. Anti-CCP antibodies: The past, the present and the future. Nat. Rev. Rheumatol. 7, 391\u2013398 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"89502_CR9","doi-asserted-by":"publisher","first-page":"102470","DOI":"10.1016\/j.jaut.2020.102470","volume":"113","author":"T Colasanti","year":"2020","unstructured":"Colasanti, T. et al. Homocysteinylated alpha 1 antitrypsin as an antigenic target of autoantibodies in seronegative rheumatoid arthritis patients. J. Autoimmun. 113, 102470 (2020).","journal-title":"J. Autoimmun."},{"key":"89502_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/annrheumdis-2014-206785","volume":"75","author":"M Juarez","year":"2016","unstructured":"Juarez, M. et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann. Rheum. Dis. 75, 1099\u20131107 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR11","doi-asserted-by":"publisher","first-page":"19263","DOI":"10.1038\/s41598-020-73919-y","volume":"10","author":"L Rodriguez-Mart\u00ednez","year":"2020","unstructured":"Rodriguez-Mart\u00ednez, L. et al. Improved classification of rheumatoid arthritis with a score including anti-acetylated ornithine antibodies. Sci. Rep. 10, 19263 (2020).","journal-title":"Sci. Rep."},{"key":"89502_CR12","doi-asserted-by":"publisher","first-page":"17372","DOI":"10.1073\/pnas.1114465108","volume":"108","author":"J Shi","year":"2011","unstructured":"Shi, J. et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl. Acad. Sci. U. S. A. 108, 17372\u201317377 (2011).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"89502_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/annrheumdis-2013-204154","volume":"73","author":"J Shi","year":"2014","unstructured":"Shi, J. et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann. Rheum. Dis. 73, 780\u2013783 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/art.37830","volume":"65","author":"J Shi","year":"2013","unstructured":"Shi, J. et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheumatol. 65, 911\u2013915 (2013).","journal-title":"Arthritis Rheumatol."},{"key":"89502_CR15","doi-asserted-by":"publisher","first-page":"e0161141","DOI":"10.1371\/journal.pone.0161141","volume":"11","author":"A Montes","year":"2016","unstructured":"Montes, A. et al. Anti-carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies. PLoS ONE 11, e0161141 (2016).","journal-title":"PLoS ONE"},{"key":"89502_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-015-0536-2","volume":"17","author":"M Brink","year":"2015","unstructured":"Brink, M. et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res. Ther. 17, 25 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"89502_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/annrheumdis-2015-208870","volume":"76","author":"S Ajeganova","year":"2017","unstructured":"Ajeganova, S. et al. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: A study exploring replication and the added value to ACPA and rheumatoid factor. Ann. Rheum. Dis. 76, 112\u2013118 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR18","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/art.40237","volume":"69","author":"M-E Truchetet","year":"2017","unstructured":"Truchetet, M.-E. et al. Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: Data from the French ESPOIR cohort. Arthritis Rheumatol. 69, 2292\u20132302 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"89502_CR19","doi-asserted-by":"publisher","first-page":"e0202583","DOI":"10.1371\/journal.pone.0202583","volume":"13","author":"C Regueiro","year":"2018","unstructured":"Regueiro, C. et al. Association of high titers of anti-carbamylated protein antibodies with decreased bone mineral density in early arthritis patients. PLoS ONE 13, e0202583 (2018).","journal-title":"PLoS ONE"},{"key":"89502_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2019-216709","volume":"79","author":"R Castellanos-Moreira","year":"2020","unstructured":"Castellanos-Moreira, R. et al. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: Evidence of a new autoantibody linked to interstitial lung disease. Ann. Rheum. Dis. 79, 587\u2013594 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR21","doi-asserted-by":"publisher","first-page":"e0180144","DOI":"10.1371\/journal.pone.0180144","volume":"12","author":"L Vidal-Bralo","year":"2017","unstructured":"Vidal-Bralo, L. et al. Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. PLoS ONE 12, e0180144 (2017).","journal-title":"PLoS ONE"},{"key":"89502_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1136\/annrheumdis-2015-207326","volume":"75","author":"JH Humphreys","year":"2016","unstructured":"Humphreys, J. H. et al. Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: Results from the Norfolk Arthritis Register. Ann. Rheum. Dis. 75, 1139\u20131144 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR23","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1136\/annrheumdis-2015-208954","volume":"75","author":"S Ajeganova","year":"2016","unstructured":"Ajeganova, S., Svensson, B., Huizinga, T. W. J., van der Helm-van Mil, A. H. M. & van Steenbergen, H. W. Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis. Ann. Rheum. Dis. 75, e14 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR24","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/art.40678","volume":"70","author":"VFAM Derksen","year":"2018","unstructured":"Derksen, V. F. A. M. et al. Anti-carbamylated protein antibodies and higher baseline disease activity in rheumatoid arthritis-A replication study in three cohorts: Comment on the article by Truchetet et al. Arthritis Rheumatol. 70, 2096\u20132097 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"89502_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00296-019-04253-4","volume":"39","author":"MK Nisar","year":"2019","unstructured":"Nisar, M. K. Early arthritis clinic is effective for rheumatoid and psoriatic arthritides. Rheumatol. Int. 39, 657\u2013662 (2019).","journal-title":"Rheumatol. Int."},{"key":"89502_CR26","first-page":"S100","volume":"21","author":"J van Aken","year":"2003","unstructured":"van Aken, J., van Bilsen, J. H., Allaart, C. F., Huizinga, T. W. & Breedveld, F. C. The Leiden early arthritis clinic. Clin. Exp. Rheumatol. 21, S100\u2013S105 (2003).","journal-title":"Clin. Exp. Rheumatol."},{"key":"89502_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/rheumatology\/kem343","volume":"47","author":"G Orozco","year":"2008","unstructured":"Orozco, G. et al. Auto-antibodies, HLA and PTPN22: Susceptibility markers for rheumatoid arthritis. Rheumatology (Oxford) 47, 138\u2013141 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"89502_CR28","doi-asserted-by":"publisher","first-page":"e29492","DOI":"10.1371\/journal.pone.0029492","volume":"6","author":"I Gonz\u00e1lez-\u00c1lvaro","year":"2011","unstructured":"Gonz\u00e1lez-\u00c1lvaro, I. et al. Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS ONE 6, e29492 (2011).","journal-title":"PLoS ONE"},{"key":"89502_CR29","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 62, 2569\u20132581 (2010).","journal-title":"Arthritis Rheumatol."},{"key":"89502_CR30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson, D. T. et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheumatol. 36, 729\u2013740 (1993).","journal-title":"Arthritis Rheumatol."},{"key":"89502_CR31","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha, D. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res. Ther. 7, R796-806 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"89502_CR32","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/acr.21854","volume":"65","author":"I Castrej\u00f3n","year":"2013","unstructured":"Castrej\u00f3n, I. et al. Development and validation of a new disease activity index as a numerical sum of four variables in patients with early arthritis. Arthritis Care Res. (Hoboken) 65, 518\u2013525 (2013).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"89502_CR33","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","volume":"41","author":"AM van Gestel","year":"1998","unstructured":"van Gestel, A. M., Haagsma, C. J. & van Riel, P. L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheumatol. 41, 1845\u20131850 (1998).","journal-title":"Arthritis Rheumatol."},{"key":"89502_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce, B. & Fries, J. F. The Stanford Health Assessment Questionnaire: Dimensions and practical applications. Health Qual. Life Outcomes 1, 20 (2003).","journal-title":"Health Qual. Life Outcomes"},{"key":"89502_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1526-5900(03)00716-8","volume":"4","author":"MP Jensen","year":"2003","unstructured":"Jensen, M. P., Chen, C. & Brugger, A. M. Interpretation of visual analog scale ratings and change scores: A reanalysis of two clinical trials of postoperative pain. J. Pain 4, 407\u2013414 (2003).","journal-title":"J. Pain"},{"key":"89502_CR36","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/annrheumdis-2013-205079","volume":"74","author":"MM Ward","year":"2015","unstructured":"Ward, M. M., Guthrie, L. C. & Alba, M. I. Clinically important changes in individual and composite measures of rheumatoid arthritis activity: Thresholds applicable in clinical trials. Ann. Rheum. Dis. 74, 1691\u20131696 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3899\/jrheum.090449","volume":"37","author":"MK Kvamme","year":"2010","unstructured":"Kvamme, M. K., Kristiansen, I. S., Lie, E. & Kvien, T. K. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J. Rheumatol. 37, 26\u201331 (2010).","journal-title":"J. Rheumatol."},{"key":"89502_CR38","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/art.24282","volume":"61","author":"D Aletaha","year":"2009","unstructured":"Aletaha, D., Funovits, J., Ward, M. M., Smolen, J. S. & Kvien, T. K. Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline. Arthritis Rheumatol. 61, 313\u2013320 (2009).","journal-title":"Arthritis Rheumatol."},{"key":"89502_CR39","doi-asserted-by":"publisher","first-page":"e0161727","DOI":"10.1371\/journal.pone.0161727","volume":"11","author":"I Gonz\u00e1lez-\u00c1lvaro","year":"2016","unstructured":"Gonz\u00e1lez-\u00c1lvaro, I. et al. Cut-offs and response criteria for the Hospital Universitario La Princesa Index (HUPI) and their comparison to widely-used indices of disease activity in rheumatoid arthritis. PLoS ONE 11, e0161727 (2016).","journal-title":"PLoS ONE"},{"key":"89502_CR40","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/acr.22606","volume":"67","author":"JR Curtis","year":"2015","unstructured":"Curtis, J. R. et al. Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients. Arthritis Care Res. (Hoboken) 67, 1345\u20131353 (2015).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"89502_CR41","doi-asserted-by":"publisher","first-page":"12023","DOI":"10.1038\/s41598-017-09657-5","volume":"7","author":"C Regueiro","year":"2017","unstructured":"Regueiro, C. et al. Value of measuring anti-carbamylated protein antibodies for classification on early arthritis patients. Sci. Rep. 7, 12023 (2017).","journal-title":"Sci. Rep."},{"key":"89502_CR42","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1080\/01621459.1995.10476615","volume":"90","author":"RJA Little","year":"1995","unstructured":"Little, R. J. A. Modeling the drop-out mechanism in repeated-measures studies. J. Am. Stat. Assoc. 90, 1112 (1995).","journal-title":"J. Am. Stat. Assoc."},{"key":"89502_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev.publhealth.25.102802.124410","volume":"25","author":"TE Raghunathan","year":"2004","unstructured":"Raghunathan, T. E. What do we do with missing data? Some options for analysis of incomplete data. Annu. Rev. Public Health 25, 99\u2013117 (2004).","journal-title":"Annu. Rev. Public Health"},{"key":"89502_CR44","doi-asserted-by":"publisher","DOI":"10.3768\/rtipress.2009.mr.0009.0903","volume-title":"A Mixed Model Approach for Intent-to-Treat Analysis in Longitudinal Clinical Trials with Missing Values","author":"H Chakraborty","year":"2009","unstructured":"Chakraborty, H. & Gu, H. A Mixed Model Approach for Intent-to-Treat Analysis in Longitudinal Clinical Trials with Missing Values (RTI Press, 2009)."},{"key":"89502_CR45","unstructured":"jamovi (The jamovi project, 2021)."},{"key":"89502_CR46","first-page":"319.1","volume":"78","author":"C Regueiro","year":"2019","unstructured":"Regueiro, C. et al. Persistent high disease activity in the anti-carbamylated protein antibody positive early arthritis patients independently of treatment. Ann. Rheum. Dis. 78, 319.1-319 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"89502_CR47","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/acr.22902","volume":"68","author":"C Desthieux","year":"2016","unstructured":"Desthieux, C., Hermet, A., Granger, B., Fautrel, B. & Gossec, L. Patient\u2013physician discordance in global assessment in rheumatoid arthritis: A systematic literature review with meta-analysis. Arthritis Care Res. (Hoboken) 68, 1767\u20131773 (2016).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"89502_CR48","doi-asserted-by":"publisher","first-page":"e125278","DOI":"10.1172\/jci.insight.125278","volume":"4","author":"MH Chang","year":"2019","unstructured":"Chang, M. H. & Nigrovic, P. A. Antibody-dependent and -independent mechanisms of inflammatory arthritis. JCI Insight 4, e125278 (2019).","journal-title":"JCI Insight"},{"key":"89502_CR49","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13075-019-2079-4","volume":"21","author":"C Regueiro","year":"2019","unstructured":"Regueiro, C. et al. Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: Analysis in two early arthritis clinics. Arthritis Res. Ther. 21, 280 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"89502_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-020-02182-3","volume":"22","author":"BT van Dijk","year":"2020","unstructured":"van Dijk, B. T., Trouw, L. A., van der Helm-van Mil, A. H. M. & Huizinga, T. W. J. Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: Response to the article by Regueiro et al. Arthritis Res. Ther. 22, 85 (2020).","journal-title":"Arthritis Res. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89502-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89502-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89502-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T08:03:22Z","timestamp":1670054602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89502-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89502"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89502-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"27 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9945"}}